Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00076232 · ClinicalTrials.gov registry record · Phase 3
A Study of Acyclovir to Help Prevent HIV Infection in People With Genital Herpes
A Phase 3 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 3
- Development phase
- 3,682
- Enrollment target
NCT00076232: Completed Phase 3 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00076232 is a Phase 3 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 3,682 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (377% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00076232, a Phase 3 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,682 participants
- Enrollment target
Study Summary
Genital herpes (HSV-2) is the most common cause of genital sores worldwide, and the presence of genital sores is a significant risk factor for becoming infected with HIV. This study will test the effectiveness of twice-daily dosing of acyclovir, a commonly prescribed anti-herpes drug, in preventing HIV infection in HSV-2 infected women who sleep with men (WSM) and men who sleep with men (MSM). Study hypothesis: Given that genital herpes is a significant risk factor to HIV acquisition, twice-daily HSV-2 suppressive therapy - 400 mg of acyclovir - will prevent HIV infection among high risk, HSV-2 seropositive WSM and MSM.
Interventions
- DRUG Acyclovir
- DRUG Acyclovir placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,682 participants |
| Start Date | 2005-04 |
| Est. Completion | 2007-11 |
| Phase | Phase 3 |
What the finished NCT00076232 record still lists
NCT00076232 is an interventional study that assigns participants to a tested intervention. Its 3,682 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (377% higher).
The record links to 0 conditions, and to 2 interventions - of which Acyclovir is the first listed.
NCT00076232 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00076232 about?
NCT00076232 is a clinical study titled "A Study of Acyclovir to Help Prevent HIV Infection in People With Genital Herpes". Genital herpes (HSV-2) is the most common cause of genital sores worldwide, and the presence of genital sores is a significant risk factor for becoming infected with HIV. This study will test the effectiveness of twice-daily dosing of acyclovir, a commonly prescribed anti-herpes drug, in preventing ...
What is the current status of trial NCT00076232?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,682 participants. The study started on 2005-04. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00076232?
The interventions under investigation include: Acyclovir (DRUG), Acyclovir placebo (DRUG).
Who is sponsoring clinical trial NCT00076232?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00076232's enrollment target sits among peer trials
3,682 66th of 2000 higher than 1,935 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06058377 · 3,680 participants · Phase 3
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
- NCT06784960 · 3,689 participants · NA
Communication Strategies to Increase HPV Vaccination Intention
- NCT06401863 · 3,691 participants · NA
Shared Decision for Drug Interactions in Oral Anticoagulation
- NCT06702553 · 3,650 participants · Phase 3
Nitric Oxide for Reduced Intensive Support in Cardiac Surgery With Cardiopulmonary Bypass
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia